Bestaande gebruiker? Log in
Abonneren
Home
Beurs vandaag
Koersen
Nieuws
Agenda
Analisten
Analisten vandaag
Meest aanbevolen aandelen
Minst aanbevolen aandelen
Aandelen met grootste potentieel
Insider trading
Insiders vandaag
Meest gekochte aandelen
Meest verkochte aandelen
Mijn Trivano
Mijn Trivano
Mijn selecties
Mijn nieuwsbrieven
Abonneren
Beurs vandaag
Koersen
Nieuws
Agenda
Analisten
Insider trading
Mijn Trivano
Registreren / inloggen
Beurs vandaag
Amerika
Iterum Therapeutics Plc
Nieuws
Iterum Therapeutics Plc
ITRM
NAS
: ITRM
| ISIN: IE00BF3W0Q35
14/11/2024
1,360 USD
(-4,90%)
(-4,90%)
14/11/2024
Aandeel volgen
Aandeel gevolgd
Samenvatting
Nieuws
Insiders
Technische analyse
TA
Toon enkel gratis nieuws
30 januari 2024 ·
Iterum Therapeutics Announces Positive Topline Results from its Phase 3 REASSURE Clinical Trial of Oral Sulopenem in Uncomplicated Urinary Tract Infections
· Persbericht
30 september 2021 ·
Antimicrobials Working Group Highlights Member Company Participation at IDWeek 2021
· Persbericht
27 september 2021 ·
Iterum Therapeutics Plc (Nasdaq: Itrm) October 4, 2021 Investor Filing Deadline:
· Persbericht
25 september 2021 ·
ITRM UPCOMING DEADLINE: Investors with Substantial Losses Have Opportunity to Lead the Iterum Therapeutics plc Class Action Lawsuit
· Persbericht
9 september 2021 ·
ITERUM THERAPEUTICS (NASDAQ: ITRM) INVESTOR FILING DEADLINE: Bernstein Liebhard Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Has Been Filed Against Iterum Therapeutics plc
· Persbericht
27 augustus 2021 ·
Pomerantz Law Firm Announces the Filing of a Class Action Against Iterum Therapeutics plc and Certain Officers - ITRM
· Persbericht
20 augustus 2021 ·
Pomerantz Law Firm Announces the Filing of a Class Action Against Iterum Therapeutics plc and Certain Officers - ITRM
· Persbericht
16 augustus 2021 ·
ITRM INVESTOR FILING DEADLINE: Bernstein Liebhard Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Has Been Filed Against Iterum Therapeutics plc
· Persbericht
12 augustus 2021 ·
Pomerantz Law Firm Announces the Filing of a Class Action Against Iterum Therapeutics plc and Certain Officers - ITRM
· Persbericht
9 augustus 2021 ·
ITRM NOTICE: Investors with Substantial Losses Have Opportunity to Lead the Iterum Therapeutics plc Class Action Lawsuit
· Persbericht
6 augustus 2021 ·
Pomerantz Law Firm Announces the Filing of a Class Action Against Iterum Therapeutics plc and Certain Officers - ITRM
· Persbericht
5 augustus 2021 ·
Acurx Pharmaceuticals Joins the Antimicrobials Working Group
· Persbericht
8 juni 2021 ·
Crestone Joins Antimicrobials Working Group
· Persbericht
16 maart 2021 ·
Iterum Therapeutics Appoints Beth P. Hecht to Board of Directors
· Persbericht
12 maart 2021 ·
Iterum Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results
· Persbericht
5 maart 2021 ·
Iterum Therapeutics to Announce Fourth Quarter and Full Year 2020 Financial Results and Host Conference Call on March 12, 2021
· Persbericht
19 februari 2021 ·
Iterum Therapeutics to Present in Upcoming Investor Conferences
· Persbericht
17 februari 2021 ·
UTILITY Therapeutics Joins Antimicrobials Working Group
· Persbericht
11 februari 2021 ·
Iterum Therapeutics plc Announces Exercise of Underwriter’s Option to Purchase Additional Ordinary Shares
· Persbericht
10 februari 2021 ·
Iterum Therapeutics plc Announces $35.0 Million Registered Direct Offering of Ordinary Shares Priced At-the-Market under Nasdaq Rules
· Persbericht
Aandeel volgen
Aandeel gevolgd
Mijn selecties
Voorbeeldselectie
Je selectie is nog leeg.
Voeg nu effecten toe